Investor Expectations in MedTech

MedTech Reimbursement strategy is not optional at Series A, but its weight varies significantly by technology type. You don't need a solved reimbursement problem. You need to demonstrate you understand the path, the risks, and the capital required to get there. Founders who treat reimbursement as a post-approval problem consistently lose deals to those who've built it into product, clinical, and commercial strategy from day one.